Navigation Links
Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Date:11/11/2010

inal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. Vaccination of the first study group has been completed and demonstrated that PEV7 is safe and well-tolerated in all subjects and elicits an immune response even at low doses.

"This is an important step for both PEV7 and Pevion as we aim for proof of concept in humans with our innovative approach to disease management using a state-of-the-art subunit vaccine," comments Evert Kueppers, CEO of Pevion. "The fact that in the first volunteers we see immunogenicity at low doses of the vaccine's subunit antigen is very encouraging. In addition, the excellent tolerability of our virosome-delivered vaccines is once more confirmed in a human trial."

"A vaccine has the potential to break new ground here: the prevention of recurrencies, that no drug can provide," says Prof. Jack Sobel, a world leading specialist in the field of recurrent VVC from the Department of Internal Medicine at Wayne State University, Detroit, USA. "An efficient vaccine would bring relief to millions of women who are severely impacted by this disease."

The ongoing PEV7 Phase I study is designed to assess the safety and immunogenicity of the vaccine candidate. Half of the volunteers will receive intramuscular injections, while the other half will receive capsules, administered intravaginally. In total, the study will enroll 48 healthy women of childbearing age. Pevion's announcement follows the review by an independent Data and Safety Monitoring Board (DSMB) of the results from the first study group that received the vaccine intramuscularly at a low dose.

"The DSMB has now recommended that the trial should proceed with the next study group. This is an important development milestone," adds Kueppers. "RVVC is a major problem, as sufferers have at least four acute attacks per year with a significant effect on quality of
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
3. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
4. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
5. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
6. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
7. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
8. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
9. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
10. Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
11. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
(Date:8/29/2014)... Pursuing its deepest desires to help build ... stunning new design that promises to redefine the global ... surrogacy platform has witnessed a 42 percent increase in ... month, the FindSurrogateMother.com community is formed by hopeful parents ... — the precious gift of life. , Whether intended ...
(Date:8/29/2014)... News) -- If you have bunions, taking care of them ... expert says. A bunion is a bump that forms ... tissue moves out of place and extends beyond the normal ... pain and may require surgery to correct, said Brent Rosenthal, ... Freehold, N.J. To prevent bunions, avoid wearing shoes with ...
(Date:8/29/2014)... NEW YORK August 29, 2014 - Despite US ... obesity, there are many barriers, several of which may ... study by researchers at NYU Langone Medical Center published ... General Internal Medicine ( JGIM ). , David ... Department of Internal Medicine at NYU Langone, and colleagues ...
(Date:8/29/2014)... AURORA, Colo. (Sept. 2, 2014) A team of ... has reported the breakthrough discovery of a process to ... patients. These findings could have implications that extend beyond ... and autoimmune diseases., In an article published ... the Charles C. Gates Center for Regenerative Medicine and ...
(Date:8/29/2014)... 29, 2014 Today, NBC’s “The ... who profiled a handful of safe, back to ... Research. This year, many schools will include earphones ... innovator of hearing wellness solutions, offers the best ... Earphones, offered in yellow, pink and black, sound ...
Breaking Medicine News(10 mins):Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Take Steps to Control Bunions 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2
... N.Y., Oct. 8 Moog Inc. (NYSE:,MOG.A and ... are adopting,the Moog brand name. The organizations and ... to an expanded product portfolio within a,single, well-established ... continue to be associated with the,products, this event ...
... by Leading Architectural Firms, LISBON, Portugal ... weeks after,awarding two Johns Hopkins University scientists ... for their research in combating blindness, the,Antonio ... medical,research with the groundbreaking of its 300,000-square-foot ...
... safe substitutes for authentic,FDA approved injectables, NEW ... cosmetic injectables are a threat to your looks,and ... Safety. "The,growing acceptance of cosmetic injections for their ... cautions," says Coalition,leader, plastic surgeon Jeffrey Kenkel, MD ...
... Hodgkin lymphoma, a common form of cancer of the ... blood cells (B cells), but have lost a considerable ... phenotype and the characteristics of Hodgkin lymphoma cells are ... Delbrck Center for Molecular Medicine, MDC, Berlin-Buch and Charit ...
... of Defense has awarded The University of Texas Health ... conduct a multi-center clinical trial that could lead to ... both soldiers and civilians -- who require massive blood ... Sciences (CCTS) is contracting with the U.S. Army Institute ...
... closer to understanding the spread of deadly diseases such ... bacteria respond to stress. , The research, published in ... Science , details how a huge molecule called a ... , Scientists from the University of Newcastle in ...
Cached Medicine News:Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 2Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 3Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Hodgkin lymphoma -- new characteristics discovered 2Health News:Hodgkin lymphoma -- new characteristics discovered 3Health News:UT researchers to study massive transfusion at major trauma centers 2Health News:Protection for stressed-out bacteria identified 2
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... anesthesia solution for the MRI environment , ... ,The Narkomed MRI-2 is the only ... monitor, designed and engineered to perform, without distance ... environments of up to 3.0 Tesla. This feature ...
... Narkomed GS provides high quality ventilation ... The proven technologies of the AV2+ ... the Narkomed GS user-friendly and intuitive. ... quality Narkomed GS is the perfect ...
... facilities where space is a premium Fabius ... delivery technologies with an ergonomic and compact ... of the Draeger Infinity patient monitoring range ... environment that is a sound investment into ...
Medicine Products: